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Table 1. Cumulative incidence (CI) of neutrophil engraftment
andmedian day toANC>0.5 according to day 21 bonemarrow
S224 Poster Session IMethods:The study cohort consists of 117 consecutive patients (28
matched siblings, 25 unrelated and 64 haplo) with 115 leukemia, 1
SAA, and 1 NHL. The median age is 20 years (3-62). Conditioning
regimens: 1) Ara-C1BUCY (n5 14); 2) Ara-C1 BUFlu (n5 12). In
addition, Haplo and URD received either 3) Ara-C1 BUCY1ATG
(n 5 54) or, 4) Ara-C1BUFlu1ATG. (n 5 32) followed by unma-
nipulated G-CSF mobilized bone marrow and/or peripheral blood
(G-BMPBorG-PB). 5 patients used other regimen.GVHDprophy-
laxis: CSA, MMF and short-term MTX. Multiple linear regression
models were used for cost analysis. Variables considered were: trans-
plant type (Sibling vs. URD vs. Haplo), quality of life (QOL), D/R
sex match, patient age by decade, comorbidity, diagnoses, disease
status pre-transplant, conditioning regimen, graft type, MNC,
CD341cells, ANC and platelet engraftment, AGVHD and death.
Results: The median follow-up was 603 days (range 62 -1134).
Clinical outcomes are shown in the following table.
Table 1. Clinical Outcomes after transplantation
Sibling URD Haplo P composition and chimerism (n 5 56).P ValueTRM 100 day 0 (0-0)% 9 (2-24)% 5 (1-12)% 0.0634Day 21 BM CI Engraftment by BM Characteristic for CITRM 1 year 12 (3-27)% 15 (4-32)% 14 (7-24)% 0.9488Characteristic Sub-group (Day ANC $ 0.5) (RR , p value) ComparisonRelapse 100 day 11 (3-25)% 4 (0-16)% 3 (1-10)% 0.4640
Relapse 1 year 23 (10-40)% 19 (9-41)% 9 (3-18)% 0.2187% Total Myeloid <10% (n518) 10-50% (n518) >50% (n520) 0.017DFS 100 day 89 (70-96)% 87 (65-96)% 92 (82-97)% 0.7817Precursors 95% (27 days) 89% (27 days) 100%(22 days)DFS 1 year 65 (43-80)% 67 (37-84)% 77 (63-86)% 0.4721in Aspirate (RR 0.44, (RR 0.47, ReferenceSurvival 100 day 96 (77-99)% 91 (69-98)% 94 (84-98)% 0.7430(n556) p50.017) p50.028)Survival 1 year 84 (63-94)% 78 (49-91)% 83 (70-90)% 0.8780% Cellularity
in Core
(n556)
<5% (n521)
91% (30 days)
(RR 0.39,
p50.005)
5-9% (n515)
100% (27 days)
(RR 0.83,
p50.596)
>10% (n520)
95%(21 days)
Reference
0.005
% Total Donor
Chimerism
(n556)
<90% (n56)
67% (38 days)
(RR 0.16,
p50.001)
90-99% (n59)
100% (29 days)
(RR 0.42,
p50.026)
100% (n541)
98% (22 days)
Reference
0.001The overall median cost (range) within 100-day of transplant was
52,373USD (13,627 – 262,716). The mean cost (95% CI) of HLA
matched sibling, URD and haplo was 59,015 USD (45,537-
72,493), 61,970 USD (47,701-76,224) and 63,373 USD (54,463-
72,284) (P 5 0.8674), respectively. Multivariate cost analysis
indicated that QOL# 80, conditioning including Flu or Flu1ATG
and acute GVHD 2-4 correlated with increased cost.
Conclusion: These data suggest that transplant type (Sibling vs.
URD vs. Haplo) does not significantly effect on the clinical out-
comes and 100-day cost of transplantation. Future studies with
more patients and longer follow-up are warranted.193
TOTAL DONOR CHIMERISM IN THE DAY 21 BONE MARROW PREDICTS
SUSTAINED DONOR NEUTROPHIL ENGRAFTMENT FOLLOWING DOUBLE
UNIT CORD BLOOD TRANSPLANTATION (CBT)
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Delayed or failed engraftment is a concern after CBT, even when
using double unit grafts. Therefore, we analyzed the ability of the day
21 bone marrow (BM) composition and percent donor chimerism to
predict sustained donor neutrophil engraftment in 56 recipients of
myeloablative double unit CBT. Patients (median age 29 years,
range 2-64) were transplanted for hematological malignancies, pre-
dominantly acute leukemia. Units had infused cell doses of 2.7 
107 TNC/kg/ 1.2  105 CD341 cells/kg for the larger unit, and
1.9  107 TNC/kg/ 0.7  105 CD341 cells/kg for the smaller
unit, with a donor-recipient HLA-match of 6/6 (n3), 5/6 (n59),
and 4/6 (n50). The cumulative incidence (CI) of neutrophil engraft-
ment was 95% (95% confidence interval: 89-100), with 47 patients
engrafting with 1 unit and 6 engrafting with 2. The percentage of to-
tal myeloid precursors in the day 21 BMaspirate (median 40%, range
0-87), and the percent cellularity in the day 21 BM biopsy (median
5%, range 0-80), were both associated with neutrophil engraftment
(Table 1). However, the most critical predictor of engraftment was
the percent total donor chimerism (unit#1 1 unit#2, median
100%, range 65-100), regardless if 1 or 2 units were present (Table
1). Sustained engraftment was seen in 98% of the 41 patients who
were 100% donor at day 21 with a median day to absolute neutrophil
count (ANC) $ 0.5 of 22 days. By contrast, only 87% of the 15 pa-
tients\ 100% total donor engrafted [median day to ANC $ 0.5 31days with a relative risk (RR) 0.3, p 5 0.001]. Patients who were
\90% donor had especially poor engraftment (Table 1). The asso-
ciation between total donor chimerism and engraftment was inde-
pendent of the percentage of myeloid precursors or BM cellularity.
In patients (n 5 37) without engraftment by day 21, a sub-group
of particular clinical concern, day 21 total donor chimerism was
also significantly associated with subsequent engraftment success
(p5 0.003). No patient demographic was associated with total donor
chimerism, and the only significant graft characteristic was the in-
fused CFU dose of the engrafting unit (p 5 0.002). These findings
demonstrate the critical importance of the day 21 BM total donor
chimerism and are of practical significance in the care of double
unit CBT recipients. Further, they give interesting insights into dou-
ble unit biology and suggest that the hematopoietic potential of the
engrafting unit underlies the ability to generate complete donor chi-
merism.194
THE T-CELL EPITOPE (TCE) ALGORITHM FOR CLASSIFYING HLA-DPB1
MISMATCHES DOES NOT PREDICT CLINICAL OUTCOMES IN HSCT
Askar, M., Flanagan, P., Rybicki, L., Kalaycio, M., Pohlman, B.,
Andresen, S., Dean, R., Duong, H., Copelan, E., Bolwell, B., Sobecks, R.
Cleveland Clinic
A number of reports suggested the relevance of HLA-DPB1
matching for the outcomes of allogeneic hematopoietic stem cell
transplantation (HSCT). An algorithm for determining DPB1 mis-
match permissiveness based on T-Cell Epitopes (TCE) has been
proposed (Zino et al, Blood 2004). According to this algorithm, all
DPB1 alleles are categorized in 3 (TCE3) or 4 (TCE4) groups based
on antigenicity. Accordingly DPB1 mismatches are classified as
permissive; non-permissive in GvHD; or non-permissive in HvG
direction.
Objective: To determine whether TCE classification is associated
with HSCT outcomes. The outcomes considered in this analysis are
failure to engraft, acute GvHD, chronic GvHD, and overall survival.
Methods:We analyzed 144 unrelated donor ($ 7/8 allelematches at
A, B, C, DRB1) allogeneic transplants performed in our center be-
tween 1999-2009. HLA-DPB1 mismatches were assessed using
both TCE3 and TCE4 versions of the algorithm. Recursive parti-
tioning analysis with a log-rank splitting method was used to catego-
rize TCE variables into groups that best predict each outcome. Cox
proportional hazards analysis was used to identify prognostic factors
for each outcome.
Results:Graft failure was significantly highest among recipient with
permissive DPB1 mismatches (AHR 9.87, 95% CI 1.21-80.3, P 5
0.03) compared to recipients of zero mismatched, GvHD non-per-
missive, and HvG nonpermissive DPB1 mismatched donors. Acute
GvHD was significantly higher in all DPB1 mismatches regardless
of TCE classification (AHR 1.93, 95%CI 1.11-3.34, P5 0.02) com-
pared zeroDPB1mismatch. There was no significant association be-
tween TCE classification and chronic GvHD, or overall survival.
Poster Session I S225Conclusion:Our results indicate an increased risk of acuteGvHD in
association with DPB1 mismatch regardless of the TCE classifica-
tion. TCE classification did not correlate with any transplant out-
come considered in our cohort. This analysis does not support the
clinical relevance of ranking DPB1 mismatches based on the TCE
algorithm.195
A SCORING SYSTEM PREDICTING OUTCOME AFTER UNRELATED DONOR
STEM CELL TRANSPLANTATION IN PRIMARY REFRACTORY ACUTE MYE-
LOID LEUKEMIA
Craddock, C.F.1, Labopin, M.2, Schmid, C.3, Mohty, M.4, Rocha, V.5
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Treatment options for adults with primary refractory AML
(PREF AML) are extremely limited. Whilst sibling allogeneic
stem cell transplantation can result in long term survival most pa-
tients lack a matched family donor and are destined to die of refrac-
tory disease. Greater availability of unrelated donors and
improvements in supportive care have increased the proportion
of patients with PREFAML in whom allografting is technically fea-
sible but the outcome of unrelated donor transplantation in this
population has not been extensively studied. We therefore analysed
overall survival in 168 patients with PREF AML who underwent
unrelated donor transplantation between 1994 and 2006 with a me-
dian follow-up of 59 months (15-172). 80 patients received three or
more courses of induction chemotherapy. The median percentage
of bone marrow (BM) blasts at transplant was 39%. The 5-year
overall survival for the whole group was 22%. In multivariate anal-
ysis, fewer than three courses of induction chemotherapy, a lower
percentage of BM blasts at transplant and patient CMV seropositiv-
ity were associated with improved survival. We used the prognostic
factors identified in multivariate analysis to develop a scoring sys-
tem. This allowed the delineation of four prognostic groups with
survival rates ranging between 446 11% and 0%. This study dem-
onstrates an important role for unrelated donor transplantation in
the management of selected patients with PREFAML and confirms
the importance of initiating an urgent unrelated donor search in pa-
tients with no matched sibling donor who fail to respond to induc-
tion chemotherapy. Pre-transplant factors allow the identification
of patients with PREF AML who are likely to benefit from unre-
lated donor transplantation.196
HLA DISPARITY AND RAPID IMMUNE RECONSTITUTION DO NOT OVER-
COME PROPENSITY TO RELAPSE IN PATIENTS UNDERGOING HAPLOI-
DENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) WITH
PERSISTENT DISEASE AT THE TIME OF TRANSPLANT
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While increasing HLA disparity is known to be associated with
increased risk of significant graft versus host disease (GVHD),
there is less data as to whether increasing HLA disparity is corre-
lated with stronger, clinically significant graft versus leukemia ef-
fects. We examined a group of patients with acute leukemia
undergoing haploidentical HSCT to assess whether 1) there was
a marked difference in relapse rates based on the degree of HLA
mismatch and 2) if early recovery of donor lymphoid subpopula-
tions was associated with less relapse after HLA mismatched
HSCT. Thirty-four adult patients with AML (24) and ALL (10)
underwent haploidentical HSCT between 2005 and 2009 using
a 2 step process which separates the infusion of the lymphoid and
myeloid portions of the graft while attempting to render thelymphocytes tolerant utilizing cyclophosphamide. The patients re-
ceived 2 x10e8/kg donor CD3 cells (DLI) after conditioning with
either TBI 12 Gy (N 5 24) or fludarabine 30 mg/m2  4, thiotepa
5 mg/m2  3, and TBI 2 Gy (N 5 10). Two days after the DLI, all
patients received cyclophosphamide (CY) 60 mg/kg  2 followed
by a CD 34 selected donor product. The TBI based regimen was
given to 80% of patients with ALL and 56% with AML. We exam-
ined relapse rates based on the number of antigen mismatches at A,
B, Cw, and DRB1 in the GVH direction. There were no discern-
able differences based on degree of HLA disparity with even the
most haplodisparate group exhibiting high rates of relapse when
disease was present at HSCT. In contrast, the presence of active
leukemia at the time of HSCT had far more impact on subsequent
relapse rates (see Table).
Table 1. Outcomes Based on Degree of HLA Disparity
4 Antigen 3 Antigen 2 Antigen 1 AntigenMismatch Mismatch Mismatch MismatchNumber of
PatientsRelapsed/
TotalRelapsed/
TotalRelapsed/
TotalRelapsed/
TotalActive Disease
at HSCT17 (50%) 10/12 (83%) 2/2 (100%) 3/3 (100%) N/ACR at HSCT 17 (50%) 3/9 (33%) 1/7 (14%) N/A 0/1 (0%)Total 13/21 (62%) 3/9 (33%) 3/3 (100%) 0/1 (0%)We also examined the impact of immune recovery on relapse. Ab-
solute numbers of NK, and CD4 and CD8 T cells were examined in
the first 4 months post HSCT. T cell, MNC, and total chimerism
was greater than 99% donor-derived at the time of the assessment.
For patients who did or did not relapse post HSCT the median
numbers of lymphoid subsets (cells/uL) were: NK 165 (77-700)
vs 209 (77-660), CD4 105 (18-245) vs 98 (10-403), and CD8 82
(9-1039) vs 176 (2-2380) respectively. In this small series of patients
treated with the 2 step transplant method, relapse was associated
more with the presence of disease at HSCT than with any discern-
able trend in degree of HLA disparity or early immunologic recov-
ery. Other approaches to treat resistant leukemia are required
to substantially improve disease free survival in these high risk
patients.197
ANTI-HLA ANTIBODIES PREDICT GRAFT FAILURE, TIME TO ENGRAFT-
MENT AND UMBILICAL CORD UNIT DOMINANCE IN DOUBLE UMBILICAL
CORD BLOOD TRANSPLANTATION
Cutler, C.1, Kim, H.T.2, Sun, L.2, Sese, D.3, Kao, G.1, Vasquez, M.1,
Armand, P.1, Koreth, J.1, Ho, V.T.1, Alyea, E.1, Soiffer, R.J.1,
Ballen, K.1, Ritz, J.1, Milford, E.3, Antin, J.H.1 1Dana-Farber Cancer
Institute, Boston, MA; 2Dana-Farber Cancer Institute, Boston, MA;
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Anti-HLA antibodies (HLA-Ab) predict graft failure in unrelated
donor and single umbilical cord blood (UCB) transplantation. We
measured HLA-Ab in double UCB transplantation (DUCBT) with
the hypothesis that HLA-Ab would predict time to engraftment,
graft failure and UCB unit dominance.
Methods: 73 patients with banked pre-transplant sera who under-
went DUCBT using 4/6 or better allelic HLA-matched UCB
units (2004 -2008) were studied. Labscreen (One Lambda Inc.)
was used to capture class I/II HLA-Ab and the Luminex100 IS
system was used to detect fluorescent tagged binding of human
IgG. Visual software was used to normalize results and to deter-
mine the presence of mixed class I/II HLA-Ab. Positive samples
were tested using single antigen-coated microbeads. Beads with
a 1000 mean fluorescent intensity above baseline were considered
positive. Chimerism was measured using STR typing of informa-
tive alleles. Graft failure was defined as the absence of neutrophil
engraftment 42 days from DUCBT or loss of UCB chimerism by
day 100 without malignant relapse. UCB dominance was defined
as . 90% contribution to hematopoiesis by a single UCB unit at
day 100.
